Select a year:
Select a category:

4Moving Biotech at EULAR 2021

Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021. For further&hellip

Read More

4P-Pharma at BIO Digital 2021

4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion. Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships. She is looking forward&hellip

Read More

The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach

4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.&hellip

Read More

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people&hellip

Read More

4Moving Biotech at the OARSI Connect 2021 online event

A poster on our latest results on 4P004 entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (#435) will be presented during the OARSI Connect online event on 2021 April 29-May 1, by Pr. Francis Berenbaum (4Moving Biotech’s CEO/CMO, Head of Rheumatology department at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France).&hellip

Read More

4P-Pharma at BIO Europe Spring 2021

Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!

Read More